Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ: DXCM )

84.38 -0.46 (-0.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,135,597
Open 86.32
Bid (Size) 83.90 (1)
Ask (Size) 84.24 (4)
Prev. Close 84.84
Today's Range 83.89 - 86.33
52wk Range 62.34 - 142.00
Shares Outstanding 390,600,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Outlook: DexCom Through The Eyes Of 11 Analysts
Via Benzinga
Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga

Performance

YTD
+7.49%
+7.49%
1 Month
+5.42%
+5.42%
3 Month
+16.21%
+16.21%
6 Month
-24.42%
-24.42%
1 Year
-34.74%
-34.74%

More News

Read More
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
Is NASDAQ:DXCM on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
2 Healthcare Stocks to Buy Hand Over Fist in January
Via The Motley Fool
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook
From DexCom, Inc.
Via Business Wire
NASDAQ:DXCM qualifies as a high growth stock and is consolidating.
Via Chartmill
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
Via The Motley Fool
Health Tracking Is Moving To Smart Rings From Watches. Oura Leads Market.
Via Investor's Business Daily
3 Beaten-Down Stocks That May Be Due for Big Comebacks in 2025
Via The Motley Fool
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
From DexCom, Inc.
Via Business Wire
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
Via The Motley Fool
DEXCOM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of DexCom, Inc. - DXCM
From Kahn Swick & Foti, LLC
Via Business Wire
Peering Into DexCom's Recent Short Interest
Via Benzinga
Key Takeaways From DexCom Analyst Ratings
Via Benzinga
3 Reasons to Buy DexCom Stock Like There's No Tomorrow
Via The Motley Fool
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
From DexCom, Inc.
Via Business Wire
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Via Benzinga
Exploring the Growth Potential of NASDAQ:DXCM as It Nears a Breakout.
Via Chartmill
2 Excellent Healthcare Stocks to Hold Through the Next Decade
Via The Motley Fool
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over
Via The Motley Fool
2 Superior Growth Stocks to Buy Right Now If You have $1,000 to Invest
Via The Motley Fool
Dexcom and ŌURA Announce Strategic Partnership
From DexCom, Inc.
Via Business Wire
Large-Cap Stocks In Trouble - Sunday, Nov. 17
Via Talk Markets
Tiger Global Hedge Fund Buys Flutter Entertainment Stock, Sells DexCom
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.